Renaissance Technologies LLC Lowers Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Renaissance Technologies LLC decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 26.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,847 shares of the medical research company's stock after selling 16,753 shares during the period. Renaissance Technologies LLC's holdings in IQVIA were worth $9,206,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of IQV. Synergy Asset Management LLC bought a new position in shares of IQVIA during the fourth quarter valued at approximately $33,000. Lee Danner & Bass Inc. purchased a new stake in shares of IQVIA in the 4th quarter worth about $44,000. Zions Bancorporation N.A. boosted its stake in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares in the last quarter. Versant Capital Management Inc raised its stake in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after buying an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in IQVIA in the fourth quarter worth about $60,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Stock Performance

Shares of IQV stock traded up $6.60 during trading hours on Wednesday, reaching $150.21. 638,838 shares of the company traded hands, compared to its average volume of 1,412,090. The firm has a 50-day moving average price of $174.25 and a 200 day moving average price of $195.42. The company has a market cap of $26.48 billion, a P/E ratio of 20.03, a P/E/G ratio of 1.99 and a beta of 1.46. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on IQV. Mizuho cut their price objective on shares of IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. JPMorgan Chase & Co. lowered their price target on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. Stifel Nicolaus reduced their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Royal Bank of Canada reiterated an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Finally, UBS Group cut their target price on IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Six equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $241.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.